Prostate cancer is a major cause of mortality in men in the Western world.
macrophage colony-stimulating factor, demonstrated in a phase III, placebocontrolled trial an improvement in median time to disease progression. The improvement in overall survival was 4.5 months for sipuleucel-T-treated patients compared with the placebo group.
Although there is a minor increase in overall survival of metastatic prostate cancer patients with some approaches, more effective therapeutic strategies need to be developed.
Prostate cancer is the most frequently diagnosed testosterone therapy, consisting of either bilateral orchidectomy or hormonal therapy using estrogens cancer among men, with 234 460 new cases being or analogues of hypothalamic luteinising hormoneexpected in 2006 in the US alone, and the third releasing hormone. Some tumour cells eventually leading cause of cancer-related deaths in both the become androgen-independent and progress rapidly. US and Europe.
[1] Although localised prostate canPatients with locally advanced or disseminated mecer is often curable, metastatic hormone-indepentastases usually succumb with hormone-refractory dent prostate cancer is usually fatal and 27 350 men disease. Because there is presently no effective therwere expected to die of prostate cancer in the US in apy available for such advanced tumours, it is cru-2006.
[1] In recent years, the mortality rate for proscial to develop novel therapeutic tools against prostate cancer may have been reduced as a result of tate cancer. early diagnosis using detection techniques such as digital rectal examination and screening for pros-
The objective of this article is to review curtate-specific antigen (PSA). Nearly three decades rent knowledge and recent developments in the ago, PSA was first examined as a serum marker for treatment of prostate cancer patients, including anthe early detection of prostate cancer.
[2] The 34 kDa tibody-, DNA-, whole cell-, viral-and dendritic cellglycoprotein PSA is a serine protease belonging to based immunotherapy. In order to compare immuthe glandular kallikrein gene family and is produced notherapeutic strategies with conventional strateby prostatic epithelial cells lining the glandular acini gies, such as chemotherapy and cytokine treatment, and ducts. When PSA is secreted into prostatic and recent advances in these fields are also included in seminal fluid, it hydrolyses seminal vesicle proteins this review. important in semen liquefaction. [3] Treatment of early stage (localised) prostate can-1. Chemotherapy cer includes radical prostatectomy, external beam radiotherapy, brachytherapy (interstitial radiotheraAlthough metastatic prostate cancer initially repy) and surveillance (also known as expectant man-sponds well to androgen deprivation therapy, most agement, watchful waiting or observation). After cancers eventually develop resistance. Patients with radical prostatectomy, serum PSA drops rapidly and metastatic androgen-independent prostate cancer should be undetectable within 3 or 4 weeks. Within have a progressive and morbid disease with an esti-5 years, 15-40% of resected patients exhibit a rise in mated median survival of 12 months. [5] Chemother-PSA level above the limit of detection. [4] About one-apy can reduce serum PSA levels in patients with third of newly diagnosed patients have advanced or hormone-refractory prostate cancer and relieves metastatic prostate cancer and are treated with anti-pain in some patients, but tolerability is a concern.
1.1 Mitoxantrone serum PSA level and quality of life were observed, compared with mitoxantrone plus prednisone treatMitoxantrone is an anthracenedione that has ment. However, Berry et al. [18] found no difference demonstrated activity against a variety of malignan-between docetaxel plus estramustine and mitoxancies. [6, 7] Kantoff et al. [8] treated 242 patients with trone plus prednisone treatment in pain palliation in hormone-refractory prostate cancer with either patients with advanced stage prostate cancer. mitoxantrone and hydrocortisone or hydrocortisone Cabrespine et al. [19] compared treatment with the alone. Treatment was well tolerated but no improve-taxane paclitaxel and carboplatin versus mitoxanment in survival was observed with either approach, trone in patients with hormone-refractory prostate although mitoxantrone plus hydrocortisone reduced cancer. Paclitaxel treatment leads to microtubular pain and improved quality of life in some men with stabilisation resulting in mitotic arrest at the G2/M advanced, hormone-refractory prostate cancer. Mi-transition of the mitotic cell cycle. [20] Paclitaxel also toxantrone and hydrocortisone also generated more facilitates apoptosis by inducing tubulin polymerisafrequent responses to treatment and a delay in both tion and Bcl-2 phosphorylation. [10, 21] The PSA retime to treatment failure and disease progression sponse to paclitaxel and carboplatin in the study by compared with hydrocortisone alone.
Cabrespine et al. [19] was significantly greater than the response to mitoxantrone. The median survival 1.2 Taxanes was 14.5 months for the paclitaxel and carboplatin arm compared with 11.1 months for the mitoxanDocetaxel, which belongs to the taxane class trone arm, but the paclitaxel and carboplatin arm had of chemotherapy drugs, acts by forming stable significantly greater rates of sensitive neuropathy. microtubule bundles and phosphorylating the memOh et al. [22] evaluated mitoxantrone treatment brane protein Bcl-2 in vitro, leading to its inactiva-followed by taxane-based treatment or vice versa in tion and to eventual cell death by apoptosis. [9, 10] 68 patients with hormone-refractory prostate cancer. Docetaxel is derived from the needles of the Europe-The response rate to taxane-based chemotherapy an yew tree (Taxus baccata). Administration of was greater than the response rate to mitoxantrone this medication has been shown in several phase II treatment; however, total progression-free survival studies to reduce serum PSA levels in >50% of was similar, irrespective of whether taxane-based patients. [11, 12] Furthermore, the combination of chemotherapy was administered first or second. docetaxel and either estramustine or calcitriol has led to a reduction in PSA levels in >80% of pa-
Epothilones
tients. [13] [14] [15] Docetaxel plus estramustine chemotherapy for metastatic, hormone-refractory prostate canEpothilones A and B are new classes of cytotoxic cer has been shown to significantly prolong life by agents that, similarly to paclitaxel, cause microtubuapproximately 2-3 months, compared with the pre-lar stabilisation and mitotic arrest. Treatment of vious standard therapy mitoxantrone plus pred-chemotherapy-naive patients with castrate-metastatnisone or hydrocortisone treatment. [16] Tannock et ic prostate cancer with epothilone B analogue al. [17] compared docetaxel plus prednisone and mito-(BMS-247550 or ixabepilone) and estramustine xantrone plus prednisone treatment in patients with phosphate resulted in a >50% decline in PSA in 11 advanced prostate cancer. When prednisone plus of 12 evaluable patients in one study [23] and in 31 of docetaxel was given every 3 weeks, superior surviv-45 patients in a similar study. [24] Hussain et al. [25] al and improved rates of response in terms of pain, also evaluated the effect of epothilone B analogue alone in chemotherapy-naive metastatic hormone-1.5 Triamcinolone refractory prostate cancer patients. Major toxicities were neutropenia and neuropathy. Fourteen of 48 Most patients with recurrent prostate cancer dispatients had confirmed PSA responses after treat-ease initially respond to androgen deprivation therment. Seventy-two percent of PSA responders had apy with tumour regression. However, this treatdeclines >80%, and two patients achieved an unde-ment eventually fails and the tumour becomes antectable PSA value. To evaluate the clinical cross-drogen-independent. The androgen receptor is resistance of epothilone B analogue and taxanes in implicated in disease progression. Several mutations hormone-refractory prostate carcinoma, 49 patients have been identified in the ligand binding site of the who received epothilone B analogue with or without androgen receptor in metastatic prostate cancer. It estramustine subsequently received second-line taxhas been demonstrated that the common mutation ane therapy. [26] Second-line taxane chemotherapy T877A allows binding of nonandrogenic corticosteafter epothilone B analogue resulted in a substantial roid hormones (such as deoxycorticosterone, cortifrequency of PSA declines, although patients with costerone, cortisol and cortisone) to the androgen epothilone B analogue-refractory disease were less receptor, thereby stimulating tumour cells. [29, 30] likely to respond to second-line taxane chemotherapy. Srinivas et al. [31] administered oral triamcinolone twice daily to 24 patients with androgen-indepen-
Platinum Compounds
dent prostate cancer. The corticosteroid triamcinolone does not bind to androgen receptors harbourPlatinum compounds (cisplatin, carboplatin) ing the T877A mutation, but clearly exerts potent used in chemotherapy have shown activity against corticosteroid effects through the corticosteroid reseveral human tumours. Satraplatin (JM-216, ceptor. Thus, it was hypothesised that triamcinolone BMS-182751) is a novel platinum (IV) complex might suppress endogenous corticosteroids and inwhich has also demonstrated in vitro cytotoxicity. In hibit stimulation of androgen-independent tumour a phase III trial, 50 patients with hormone-refractory growth. In this study, 29% of patients had a <50% prostate carcinoma were randomised to treatment decrease in serum PSA level and another 21% with satraplatin for 5 days plus prednisone or to achieved stable disease. The median time to proprednisone alone.
[27] Toxicity was minimal in both arms and the median overall survival was 14.9 gression was 7.5 months. The frequency of PSA months in the satraplatin plus prednisone arm com-response correlated with cortisol suppression, with 8 pared with 11.9 months when prednisone was ad-of 12 non-responders not having cortisol suppresministered alone. A >50% decrease in PSA was seen sion. in 9 of 27 patients in the satraplatin plus prednisone arm versus 2 of 23 in the prednisone only arm, 1.6 Summary supporting anti-tumour activity in the combination arm. Although satraplatin has moderate activity in Taken together, determined efforts to generate hormone-refractory prostate carcinoma when given and test new chemotherapeutics for the treatment of on a daily basis for 5 days, it is associated with prostate cancer have been rewarded with small but significant treatment-related toxicities such as significant successes but which do not lengthen life thrombocytopenia, neutropenia, anaemia, nausea, by more than a mean of 2-3 months. vomiting and diarrhoea. [28] 2. Cytokines ly expressed on many epithelial cancers, including prostate cancer. In their phase I dose escalation Cytokines are secreted low-molecular weight study in patients with advanced prostate cancer, Ko proteins that regulate the intensity and duration of et al. [34] demonstrated that this fusion protein is well the immune response by exerting a variety of effects tolerated at doses above a level demonstrating syson lymphocytes and other immune cells. These pro-temic biological activity. Further clinical studies of teins can be administered alone or in combination EMD 273066 administered alone and in combinawith vaccines. Thereby, cytokines can be given sys-tion with chemotherapeutic agents demonstrating its temically or injected directly into the tumour. Sever-benefit against prostate cancer are planned. al clinical trials have evaluated interleukin (IL)-2 or granulocyte-macrophage colony-stimulating factor GM-CSF regulates the proliferation and differentiation of myeloid precursor cells and is capable of 2.1 Interleukin-2 inducing tumour necrosis factor (TNF) and IL-1 expression (which leads to indirect T-cell activa-IL-2 is a 15 kDa glycoprotein produced by actition) as well as activation of macrophage and denvated lymphocytes that plays a major role in imdritic cell anti-tumour activity. In an efficacy evalumune regulation and is the most effective anti-tuation, patients with hormone-refractory prostate mour cytokine used in clinical trials. [32] Systemic cancer were treated with subcutaneously adminisadministration of IL-2 can be associated with setered GM-CSF.
[35] All but 1 of 12 patients expervere, potentially lethal adverse effects while the ienced a decline in PSA (median decline 32%), but a cytokine concentration around the tumour remains PSA decline >50% was seen in only one patient. In a low. In order to increase local IL-2 concentration, similar study, Rini et al. [36] demonstrated that GMBelldegrun et al. [33] conducted a phase I clinical trial CSF has a biological effect in patients with serologiinvolving 24 patients with locally advanced prostate cal progression of prostate cancer, as measured by cancer. A functional DNA-lipid complex encoding declines in PSA and modulation of PSA kinetics. In the IL-2 gene was administered intraprostatically a follow-up phase II clinical trial, 7 of 29 evaluable into the hypoechogenic tumour lesion under transpatients remained free of disease progression at a rectal ultrasound guidance. IL-2 therapy was well median of 5.1 years after the start of GM-CSF tolerated and evidence of systemic immune activatreatment. [37] An increase in the number of circulattion was observed. Transient decreases in serum ing monocytes and dendritic cells was observed PSA were seen in 16 of 24 patients on day 1, and the after 14 days of GM-CSF treatment. However, decrease persisted in 14 patients to day 8. A differSchwaab et al. [38] demonstrated that GM-CSF therent approach to increasing the cytokine concentraapy is safe but unable to induce PSA-specific T-cell tion directly around the tumour was chosen by Ko et immunity, and concluded that little therapeutic benal., [34] who used the EMD 273066 huKS-IL2 fusion efit can be attributed to this single agent. protein. This protein is composed of two molecules of IL-2 genetically fused to a humanised monoclonIn a phase II trial, patients with androgen-indeal antibody directed against human adenocarcino-pendent metastatic prostate cancer were treated with ma-associated antigen (KSA). KSA (also known as GM-CSF in combination with thalidomide. [39] In epithelial cell adhesion molecule [EpCAM] ) is high-vitro data have suggested that thalidomide has an-tiangiogenic activity, [40] and two clinical trials have cancer-specific antigens. Several promising targets investigated the effect of thalidomide in prostate for antibody treatment of prostate cancer have been cancer patients. [41, 42] In these trials, a >50% decline identified:
in PSA level was seen in <20% of patients. In the • human epidermal growth factor receptor-2 phase II trial of GM-CSF in combination with (HER-2/neu); thalidomide, [39] the treatment was well tolerated and • prostate-specific membrane antigen; 5 of 22 patients with androgen-independent meta-• prostate stem cell antigen; static prostate cancer had a >50% decline in PSA • vascular endothelial growth factor (VEGF);
level.
• polymorphic epithelial mucin;
• mindin/RG-1;
Fetal Liver Tyrosine Kinase 3 Ligand
• six-transmembrane epithelial antigen of prostate.
Fetal liver tyrosine kinase 3 (Flt3) ligand is a
Human Epidermal Growth Factor
growth and differentiation factor for dendritic cells
Receptor-2 (HER-2/neu) that produces high concentrations of circulating dendritic cells in Flt3 ligand-treated patients. In a The HER-2/neu oncoprotein is a transmembrane phase II clinical study, 32 patients with hormone-tyrosine kinase receptor of the epidermal growth refractory prostate cancer were randomly assigned factor receptor family. Its oncogenic character is to receive Flt3 ligand or placebo. [43] Dendritic cells probably based on its action on cellular cascades increased markedly in Flt3 ligand-treated patients involved in the proliferation and differentiation of and a significant slowing in velocity of PSA was epithelial cells. Different studies have reported that observed while patients were on-study, suggesting a HER-2 gene amplification and protein overexprespotential clinical application in the immunotherapy sion are observed in <60% of patients with horof prostate cancer.
mone-refractory prostate carcinoma. However, a phase II clinical trial using an antibody recognising 3. Antibody-Based Immunotherapy HER-2/neu receptor (trastuzumab) demonstrated Tumour-specific antibodies may contribute di-poor efficacy in treating hormone-refractory prosrectly to tumour destruction by antibody-mediated tate carcinoma. [45] Lara et al. [46] conducted a phase II complement-dependent cellular cytotoxicity. Alter-trial using trastuzumab plus docetaxel in HER-2-natively, antibodies to tumour-specific antigens may positive patients with prostate cancer. One hundred be coupled to cytotoxic agents or radioisotopes. patients with hormone-refractory prostate carcinoSeveral factors contribute to inefficient antibody ma were screened for HER-2 receptor. The trial was treatment of tumour patients: [44] (i) low affinity and closed because of non-feasibility due to a low HERcross-reactivity of the antibody; (ii) expression of 2-positivity rate (<20%). The authors estimated that the target not only in tumours but also in normal 1000 patients needed to be screened to complete tissue; (iii) inefficient penetration of the antibody accrual for a 40-patient efficacy trial. No patient into solid tumours; and (iv) technical problems with responded to trastuzumab alone. Schwaab et al. [47] the production of radioisotope and toxin conjugates. used a bispecific antibody (MDXH210) to target Fcγ
The fact that the prostate is a non-essential organ class I receptor (FcγRI) and HER-2/neu in patients makes prostate cancer an excellent target for an-whose prostate cancer overexpressed HER-2/neu. tibody-based therapy. Furthermore, tissue-specific The bispecific antibody targets phagocytic cells exantigens can be targeted without identification of pressing FcγRI (monocytes, macrophages, dendritic cells, interferon-γ-activated neutrophils) to tumours Recently, a recombinant prostate-specific memoverexpressing HER-2/neu. Patients received an in-brane antigen-specific single chain immunotoxin travenous infusion of the bispecific antibody three (A5-PE40) has been described as being selectively times per week for 2 weeks. The antibody was well toxic to prostate cancer cells. [52] The PE40 domain is tolerated and circulating plasma HER-2/neu levels a truncated version of Pseudomonas exotoxin A, decreased by 80% at days 12 and 29. Five of six which is not cytotoxic so long as it remains in the patients had stable PSA levels over the ≥40 day extracellular space. Once linked to a single chain course.
antibody fragment directed against a cell surface antigen (in this case prostate-specific membrane antigen) capable of internalising the exotoxin, it 3.2 Prostate-Specific Membrane Antigen becomes a potent immunotoxin. Because of its high J591 (MLN591) is a monoclonal IgG1 antibody and specific toxicity, this recombinant immunotoxin recognising the external domain of the type II trans-is a promising candidate for treatment of prostate membrane glycoprotein (100 kDa) prostate-specific cancer. membrane antigen, which is expressed primarily in prostate epithelium. Prostate-specific membrane an-4. DNA-Based Immunotherapy tigen expression increases across the range of benign prostate epithelium to prostate cancer, with the Various groups have demonstrated tumour prohighest intensity occurring in highest-grade cancers, tection using DNA immunisation in different modbut is minimally expressed in non-prostate tis-els. Vaccination with DNA has several advantages: sues.
[48] The antibody to prostate-specific membrane (i) gene sequences can be manipulated to deliver antigen can be labelled with a variety of radioiso-several epitopes stimulating specific cellular and topes, such as yttrium-90 ( 90 Y), indium-111 ( 111 In), humoral immune responses; (ii) DNA immunisation and lutetium-177 ( 177 Lu), which form stable com-is safe in humans; (iii) DNA is very stable and can plexes that are rapidly internalised after binding to be produced in large scale; and (iv) DNA vaccines prostate-specific membrane antigen at the cell sur-containing unmethylated sequential cytosine-guaface. In order to remove T-helper (Th) epitopes, nine (CpG) motifs skew the immune system to a Th1 J591 was deimmunised by humanisation of murine cell immune response. antibody variable domains.
In a mouse model, in vivo electroporation has Different studies have demonstrated the safety of emerged as a potent method for DNA vaccine delivradioconjugated J591. [49, 50] Bander et al. [49] demon-ery [53] compared with other methods. Different strated that 4 of 35 patients had a decrease in PSA animal models have demonstrated that DNA imfollowing treatment with 177 Lu-J591 and 16 of 35 munisation can elicit host immune responses to had stabilisation of PSA. In a clinical trial, Morris et PSA. Kim et al. [54] immunised mice with a DNA al. [51] treated 14 patients with progressive metastatic vaccine encoding the human PSA gene. The vaccine prostate cancer with 111 In-labelled J591. J591 was induced a strong and persistent antibody response well tolerated in repetitive dose-escalating adminis-against PSA, a significant PSA-specific Th cell trations, but only one patient showed a >50% reduc-proliferation and a cytotoxic T lymphocyte that tion in PSA level. The investigators proposed that recognised tumour cell targets expressing PSA. The future studies should target patients with a lesser safety and the immunogenicity of the DNA vaccine burden of disease than those in this study, in order to were confirmed in rhesus macaques.
[55] Marshall et maximise anti-tumour effects.
al. [56] demonstrated that mice immunised with DNA encoding PSA protected the mice from subsequent sequence. All patients who received initial inoculation with the viral vector followed by prostate-spetumour challenge. In a follow-up study, the same cific membrane antigen-plasmid boosts showed investigators demonstrated that co-administration of signs of immunisation, whereas only 50% of paa plasmid encoding IL-18 enhances Th1 immunity tients who received prostate-specific membrane anand tumour protection by a DNA vaccine. [57] Similar tigen/CD86 plasmids demonstrated successful imresults were observed when DNA encoding PSA munisation. All patients receiving prostate-specific was co-administered with plasmids coding for GMmembrane antigen/CD86 plasmids plus soluble CSF and/or IL-2. [58] In order to evaluate the safety, GM-CSF became immunised. Several responders, feasibility and biological efficacy of a plasmid-enas evidenced by a change in local disease, distant coding PSA, a phase I trial of this agent combined metastases and PSA levels, could be identified. Poswith GM-CSF and IL-2 was conducted in patients itive reactions were detected in 86% of vaccinated with hormone-refractory prostate cancer.
[59] The prostate cancer patients. [64] vaccine was safe and a PSA-specific cellular immune response together with an increase in anti-5. Whole Cell-Based Vaccines PSA IgG were observed in 2 of 3 patients after vaccination with 900μg DNA in five cycles. In a Vaccination with attenuated viral or bacterial follow-up study, patients were monitored for their vaccines often results in immunogenicity, memory ability to mount PSA-specific cellular response after cell production and subsequent protection against receiving the plasmid-encoding PSA.
[60] Interferonexposure to the live pathogen. The same immunisa-γ enzyme-linked immunosorbent spot (ELISPOT) tion concept could in theory be adapted to tumour assays demonstrated PSA-specific T cells in some immunology. Patient-derived tumour cells should patients. Analysis of other cytokines showed IL-4 be the best source of antigen, but in practice it is and IL-6 but not IL-10 producing cells after vaccinaextremely difficult to establish and maintain human tion in any of the patients.
prostate cancer cells in vitro. In order to prevent Plasmid DNA encoding prostatic acid phospha-growth of the applied tumour cells in the body, these tase was used to immunise rats. [61] The vaccine was cells must be irradiated prior to vaccination. found to be effective in eliciting prostatic acid phosOne approach that has been applied to whole-cell phatase-specific CD4 and CD8 T cells as well as immunisation is to transfect tumour cells with the prostatic acid phosphatase-specific IgG that were gene encoding GM-CSF. These genetically engidetected in a dose-dependent manner. These studies neered tumour cells, when re-infused back into the demonstrated that immunisation with DNA encod-patient, will secrete GM-CSF, enhancing differentiing prostatic acid phosphatase is safe and support ation and activation of host antigen-presenting cells. further clinical evaluation in prostate cancer pa-As dendritic cells accumulate around the tumour tients. [62] cells, the GM-CSF secreted by the tumour cells will In a phase I/II clinical trial, Mincheff et al. [63] enhance the presentation of tumour antigens to Th vaccinated prostate cancer patients with DNA en-and cytotoxic T cells by dendritic cells. In a phase I coding the extracellular domain of human prostate-study, eight patients were treated with autologous, specific membrane antigen in combination with GM-CSF-secreting, irradiated tumour cells prepared CD86-encoding plasmids and soluble GM-CSF. from ex vivo retroviral transduction of surgically The vaccine was compared with an adenovirus en-harvested cells. [65] Vaccine site biopsies manifested coding the same prostate-specific membrane antigen infiltrates of dendritic cells and macrophages and seven of eight patients exhibited activation of new statistically significant decrease in PSA elevation compared with the pre-vaccination state. Patients T-and B-cell responses against PSA antigens, as developed new oligoclonal antibodies reactive determined by delayed-type hypersensitivity reacagainst at least five identified antigens present in tions against non-transduced autologous tumour LNCaP or PC-3 cells. The dose and schedule emcells. Seven of eight vaccinated men had new anployed in this trial were at the low end of a potential tibodies recognising three polypeptides in protein dose-response relationship. Higher cell doses and a extracts derived from prostate cells; these new anmore prolonged schedule of boost injections are tibodies were not recognised in extracts from proswarranted. tate stromal cells.
Michael et al. [69] vaccinated 26 patients with A major difficulty for future clinical developasymptomatic hormone-resistant prostate cancer ment of this autologous treatment approach is the who showed increasing PSA levels but little or no low yield of autologous prostate cancer vaccine cells evaluable disease. Patients were intradermally vacrecovered using cell culture approaches to expand cinated with three irradiated allogeneic prostate cell prostate cancer cell numbers. Therefore, this aplines (OnyCap23, LNCaP, P4E6). The vaccine was proach appears clinically impractical for the conduct administered monthly and the first two doses were of large phase II studies required to assess efficacy.
supplemented with bacillus Calmette-Guérin as adTo circumvent this problem, cell lines established in juvant. The vaccine was well tolerated and 11 paculture from various individuals differing in MHC tients showed statistically significant, prolonged detissue type may provide a source of whole-cell tucreases in their PSA velocity. Median time to dismour vaccines. The efficacy of this allogeneic apease progression was 58 weeks, compared with proach bas been demonstrated in animal models historical control values of around 28 weeks. for prostate cancer. [66] Based on this finding, 60 patients with hormone-refractory prostate cancer 6. Recombinant Viral Vaccines were immunised with three cell lines in conjunction
Use of viral vaccines offers the advantage of a with the immunostimulant Mycobacterium vaccae natural way of inducing immune responses and (SRL-172). [67] The vaccine was safe and well tolerachieving high levels of transgene expression. Proated, although no significant decline in PSA could teins expressed by recombinant viruses are more be observed, which is not surprising considering the immunogenic than proteins in adjuvant. [70] Howevstage of disease in patients in this study. In contrast, er, the safety aspects of this approach have to be the immunological response was encouraging, beconsidered carefully. Two different recombinant vicause several patients had an increase in cytokine ral expression vectors have been used in prostate production, increases in specific antibodies and evicancer treatment: poxvirus and adenovirus vectors. dence of T-cell proliferation in response to the vaccination.
Poxvirus Vectors
Recently, 21 patients with PSA relapse following radical prostatectomy were immunised intradermalVaccinia and fowlpox are double-stranded DNA ly with GM-CSF-transduced, irradiated LNCaP or viruses belonging to the family of poxviruses and PC-3 cells every week for 8 weeks. [68] Use of cell have been extensively studied in different models. lines circumvented the limitation of the small size of One advantage of the poxviral vectors is the large the resected autologous prostate tumours. [65] At 20 size of the genomes, which allows the expression of weeks after the first treatment, 16 patients showed a up to seven different genes in one vector. [71] In an early study, Hodge et al. [72] used a recombinant periods than vaccinia viruses. Kaufmann et al. [80] vaccinia virus expressing human PSA to immunise evaluated the feasibility and tolerability of a prime/ rhesus monkeys. Human and rhesus PSA share 94% boost vaccine strategy using recombinant vaccinia homology between amino acid sequences. Im-virus (rV-PSA) and fowlpox virus (rF-PSA) expresmunised monkeys showed a short-lived PSA-specif-sing human PSA. Sixty-four eligible patients were ic IgM antibody response and PSA-specific T-cell randomly assigned to receive four vaccinations with responses that were maintained for up to 270 days. rF-PSA, three rF-PSA vaccines followed by one rVSeveral phase I clinical trials of vaccinia-PSA PSA vaccine, or one rV-PSA vaccine followed by demonstrated that the vaccine is well tolerated in three rF-PSA vaccines. The therapies were well men. [73, 74] A number of approaches have been devel-tolerated and a significant portion of men remained oped to further enhance the immune response to free of PSA progression after 19 months. Furthervaccinia-PSA. For example, Eder et al. [75] adminis-more, 46% of the patients treated in this trial exhibittered recombinant vaccinia virus (rV)-PSA to 33 ed an increase in PSA-specific T-cell responses. men with rising PSA levels. PSA levels in 14 of 33 There was a trend toward greater efficacy in the patients remained stable for at least 6 months after treatment group that received a priming dose of rVprimary immunisation. Additionally, ten patients PSA. were treated with the cytokine GM-CSF, which has
Another approach taken to further enhance the been reported to enhance T-cell responses. [76, 77] efficacy of poxvirus vaccines was administration of PSA-3 peptide-specific T-cell response was aug-recombinant viruses expressing costimulatory molemented at least 2-fold in five of seven patients cules in combination with poxviruses expressing possessing the correct MHC restriction element PSA. Efficient costimulation of T cells is essential (HLA-A2). In four of these five patients with an for activation, especially when weak antigens are increased PSA-specific immune response, stabilisa-involved. T-cell receptor engagement is required for tion of serum PSA levels for at least 6-11 months T-cell activation and ensures antigen specificity and was observed.
MHC restriction of the response. Nevertheless, additional signals delivered by costimulatory moleRepeated administration of vaccinia-based vaccules sustain and integrate T-cell receptor signalcines results in the rapid appearance of strong neuling, resulting in optimal cell proliferation and diftralising antibodies against the vaccinia virus itself, ferentiation. Delivery of the first signal (T-cell preventing the ability of the recombinant protein to receptor engagement) in the absence of a second induce T-cell responses after boosting. [75, 78, 79] To signal(s) (costimulation) leads to apoptosis or anerovercome this hurdle, new strategies have been degy. Anergic T cells do not produce IL-2 or proliferveloped. Use of recombinant avian pox viruses (aviate upon restimulation. Numerous costimulatory pox) such as canarypox (ALVAC) or fowlpox are molecules have been identified as playing roles in potential candidates for immunisation protocols in the initiation of immune responses by T and B that they can infect mammalian cells and express the lymphocytes. Signals provided through CD28-B7.1/ inserted transgene, but do not replicate in mammali-2 (costimulatory molecules B7.1 or B7.2) interacan cells. Lack of replication in host cells results in tions are essential for initial naive T-cell activation weak neutralising antibody responses, permitting and lead to increased IL-2 production and IL-2Rα subsequent boosting after initial exposure to these (CD25) expression. The receptors intercellular adviruses. Avipoxviruses offer the advantage of nonhesion molecule-1 (ICAM-1) and leukocyte funcpathogenicity and expression of antigens for longer tion-associated antigen-3 (LFA-3) on antigen-tion of docetaxel and poxvirus-PSA in men with presenting cells are additional costimulatory mole-metastatic androgen-independent prostate cancer. cules. DiPaola et al. [81] conducted a phase I study to Patients were immunised with rV-PSA admixed evaluate the safety and immunogenicity of vaccinia with rV-B7.1 and received sequential booster vacand fowlpox vaccine incorporating the PSA gene cinations with rF-PSA. Patients also received GMand a TRIad of COstimulatory Molecules CSF with each vaccination. In addition, 14 patients (TRICOM™). 1 The vaccine designated TRICOM™ received weekly doses of docetaxel. No deleterious contains a triad of T-cell costimulatory molecules effect on the ability to mount immune responses was (B7.1, ICAM-1 and LFA-3) in poxviral vectors. Ten observed with use of monthly vaccines in combinapatients with androgen-independent prostate cancer tion with weekly docetaxel. PSA-specific T-cell prewere treated with a recombinant vaccinia virus ex-cursor levels increased 3.33-fold irrespective of pressing PSA (PROSTVAC ® -V) followed by whether patients received vaccine and docetaxel or a booster with recombinant fowlpox virus with vaccine alone. Furthermore, it seemed that vaccine gene sequences for PSA (PROSTVAC ® -F) and either in combination with or before docetaxel ther-TRICOM™. The vaccine was well tolerated and apy may have had a positive effect on patients' PSA generated an immune response to vaccinia, although levels when compared with a historical control. no anti-PSA antibodies were induced. During the 8-week study period, four patients had stable disease
Adenoviral Vectors
with <25% increase in PSA. The PSA-specific cytotoxic T-lymphocyte response was not addressed Adenovirus (ADV; Ad)-based gene therapy posin this study.
sesses great potential for prostate cancer control. In a randomised, phase II clinical trial, Gulley et The ADV genome is composed of a linear doubleal.
[82] combined the rV-PSA vaccine with radiother-stranded DNA molecule which does not integrate apy in patients with clinically localised prostate into the host cell genome. ADV gene transcription cancer. Patients received a priming vaccine with rV-can be divided into an early and a late phase which PSA plus rV-B7.1 (vaccinia virus expressing the occur, respectively, before and after virus DNA costimulatory molecule B7.1) followed by monthly replication. Two main approaches for ADV-based booster vaccines with rF-PSA. The vaccines were gene therapy have been developed: (i) the viral administered with local GM-CSF and low-dose sys-deletion approach (replication-defective ADV); and temic IL-2. Standard external beam radiation ther-(ii) use of tissue and/or tumour-specific promoters apy was given between the fourth and sixth vaccina-(replication-competent ADV) to drive critical early tions. The vaccinations were well tolerated and 13 of viral gene expression. 17 patients receiving all eight vaccinations had an Replication-defective ADVs have the E1 and E3 increase in PSA-specific T cells of at least 3-fold genes removed, allowing for introduction of up to compared with the radiotherapy-only arm. Whether 7kb of foreign DNA. In 'suicide gene therapy', a the enhanced PSA-specific immune response can genetically modified ADV encoding the herpes simtranslate into an improved clinical outcome was not plex virus thymidine kinase (HSV-TK) gene delivaddressed in this study.
ers this gene into host cells. Administration of In another randomised, phase II clinical trial, ganciclovir, aciclovir or valaciclovir, which are poor Arlen et al.
[83] evaluated the concurrent administra-substrates for mammalian thymidine kinase, leads to phosphorylation of these drugs by HSV-TK. The CV787 destroys PSA + prostate cancer cells 10 000 phosphorylated drugs are nucleotide analogues, times more efficiently than PSA -cells. [87] In vitro which are highly toxic for mammalian cells because and in vivo (animal model) experiments have they are incorporated into DNA during cell division demonstrated that CV787-mediated replication-deand cause termination of DNA replication and cell pendent cytotoxicity is synergistic with the chemodeath. therapeutic agents paclitaxel and docetaxel.
[88] In a dose escalation phase I study, CV787 was adminisReplication-competent ADVs have the ability to tered as a single intravenous infusion to 23 patients replicate within cells, lyse those cells and infect with hormone-refractory metastatic prostate canneighbouring cells. In order to make replicationcer.
[89] Patients receiving the highest dose had decompetent ADVs tumour-or tissue-specific, the tectable CV787 genome copies in the peripheral E1A gene (which controls the viral gene expression blood throughout the 29 days of the study. All cascade) can be placed under transcriptional control patients developed antibodies to CV787 and doseof tumour-or tissue-specific promoters. Several related increases in IL-6 and IL-10 were detected in ADV systems have been investigated in localised the blood. No patient had a ≥50% decline in PSA prostate cancer clinical trials. For example, CV706
value, but five patients had a decrease in serum PSA (also named CN706 or CG7060) is a replicationof 25-49% following a single treatment. competent, E3-deleted, cytolytic Ad5-based virus that utilises PSA promoter-regulated replication and Numerous in vitro and animal studies have which has been shown to selectively kill human shown that HSV-TK gene delivery is effective prostate cancer xenografts in preclinical models. [84] against prostate cancer cell lines and prostate This restricted replication was achieved by insertion tumours in animal models. [90] [91] [92] [93] Herman et al. [94] of a minimal promoter-enhancer construct of the conducted a phase I dose escalation clinical trial of a human PSA gene 5´ of E1A, 3´ of the E1A promot-replication-deficient ADV containing the HSV-TK er, resulting in PSA-regulated expression of E1A. gene injected directly into the prostate, followed CN706 destroys human PSA + cells 400 times more by intravenous administration of the prodrug efficiently than PSA -cells. [84] In a phase I study, ganciclovir. All cultures of blood and urine specideWeese et al. [85] treated patients with different mens were negative for growth of ADV, and minidoses of CV706 delivered intraprostatically. The mal toxicity (grade 1-2) was encountered in 4 of 18 vaccine was well tolerated and five of five patients patients. Three patients, one each at the three highest treated with the highest two doses of CV706 dose levels, achieved an objective response, defined achieved a >50% reduction in PSA value. These as a decrease in serum PSA levels by ≥50% susresults suggest that CV706 treatment has potential tained for 6 weeks to 1 year. This study was the first for disease stabilisation.
to demonstrate the safety of ADV/HSV-TK plus ganciclovir gene therapy in human prostate cancer. CV787 (also named CG7870) expresses E1A
Several clinical trials of HSV-TK have subsequently under control of the rat probasin promoter and E1B demonstrated that the therapy is well tolerated in under control of the PSA promoter-enhancer. In men.
[ [95] [96] [97] [98] contrast to CV706, this virus expresses E3 (which encodes several proteins that have the capacity to Satoh et al. [99] evaluated the systemic T-cell remodulate the immune response of the host to ade-sponse after intraprostatic injection of the adenovirus-infected cells) in order to decrease the im-noviral vector HSV-TK followed by systemic admune response to the adenoviral vector itself. [86] ministration of ganciclovir or valaciclovir in combi-nation with radiotherapy. There was an increase in tion. In the study by Freytag et al., [102] an escalating dose of the Ad5-CD/TKrep virus was injected inactivated CD8 + T cells in the peripheral blood after traprostatically into 16 patients with locally recurvector injection. Addition of radiotherapy to in situ rent prostate cancer. Two days later, patients were gene therapy seemed to further increase total CD8 + given flucytosine and ganciclovir prodrug therapy T cells and activated CD4 + T cells. Fujita et al. [100] for 1 or 2 weeks. Seven of 16 (44%) patients exhibitfurther combined adenoviral in situ gene therapy ed a ≥25% decrease in serum PSA and 3 of 16 (19%) with radiotherapy and hormonal therapy. Sustained patients exhibited a ≥50% decrease in serum PSA. long-term systemic T-cell responses were noted afIn a further study, these investigators combined this ter combined radio-gene-hormonal therapy. Ayala et approach with radiation therapy. [103] As expected for al. [101] focused on the tissue effects observed in patients receiving definitive radiation therapy, all cancer foci and surrounding noncancerous prostate patients experienced significant declines in PSA. as well as evidence for local and systemic immune
The mean PSA half-life in patients administered >1 response in patients receiving intraprostatic viral week of prodrug therapy was significantly shorter injections of ADV/HSV-TK followed by 2 weeks of than in patients receiving prodrugs for only 1 week ganciclovir and prostatectomy 2-4 weeks later. Lo-(0.6 vs 2.0 months, respectively; p < 0.02) and cal (CD8 + cells and macrophages) and systemic markedly shorter than that reported previously for immune responses (CD8 + , activated CD8 + and patients treated with conventional-dose 3-dimen-IL-12) were increased in patients treated with HSVsional conformal radiation therapy alone (2.4 TK. Increased apoptosis and decreased microvessel months). density were also noted in these patients. Hence, Systemic delivery of recombinant IL-2 induces these results suggest a tumour-specific effect mediclinical responses in various malignancies. By proated by systemic and local immune responses, an viding exogenous cytokines, it may be possible to antiangiogenic effect and modulation of apoptosis.
overcome or prevent anergy of the immune effector Freytag et al. [102] developed a novel approach cells. In a phase I trial, adenovirus expressing IL-2 that utilises a lytic, replication-competent ADV (AdCAIL-2) was directly injected into the prostate 4 (Ad5-cytosine deaminase (CD)/TKrep) to deliver weeks prior to prostatectomy. [104] Histopathology a CD/HSV-1-TK fusion gene to tumours. The Ad5-demonstrated an inflammatory response consisting CD/TKrep virus itself generates a potent anti-tu-predominantly of CD3 + CD8 + T lymphocytes with mour effect by replicating in and destroying cancer areas of tumour necrosis. PSA levels declined in five cells. The therapeutic effect of the Ad5-CD/TKrep of five evaluable patients treated at the lowest dose. virus can be significantly enhanced by invoking two At higher doses, PSA values initially increased after suicide gene systems (CD/flucytosine [5-fluoro-injection, and then decreased to baseline prior to cytosine] and HSV-1-TK/ganciclovir), which render surgery. malignant cells sensitive to specific pharmacological agents and sensitise them to radiation. CD con-7. Dendritic Cell-Based Immunotherapy verts the prodrug flucytosine to fluorouracil (5-fluorouracil), which on further conversion results in Dendritic cells are the most potent antigeninhibition of thymidylate synthase and depletion of presenting cells. Interaction of dendritic cells with thymidine 5'monophosphate pools. This leads to microbial or viral products (double-stranded RNA, increased DNA strand breaks and cell cycle redistri-CpG, lipopolysaccharide), proinflammatory cybution, sensitising cells to the lethal effects of radia-tokines (TNFα, IL-1β) or after ligation of surface CD40 leads to activation of dendritic cells, resulting with PSM-P1 or PSM-P2 peptides. [107, 108, [110] [111] [112] in upregulation of costimulatory and MHC mole-GM-CSF applied as adjuvant did not significantly cules as well as changes in homing receptor expres-enhance the measured immune response after adsion. After capturing antigen in the tissues by phago-ministration of autologous dendritic cells loaded cytosis or by endocytosis, dendritic cells migrate to with PSM-P1 or PSM-P2 peptides. [113] In all of their the draining lymph node where they present the studies, Murphy and colleagues [106] [107] [108] [109] [110] [111] [112] [113] used in vitro antigen to T lymphocytes. Dendritic cells have the cultured dendritic cells without a maturation step. unique ability to prime naive T cells and elicit potent Therefore, these dendritic cells should have an imantigen-specific responses. However, vaccination of mature phenotype, and it has been reported that patients with autologous dendritic cells carries the immature dendritic cells tolerise (i.e. induce tolerdisadvantage of the tremendous technical effort re-ance in) [126, 127] rather than activate naive T cells. quired to isolate dendritic cells or precursor from Nevertheless, it might be possible that dendritic peripheral blood and mature them in vitro. Never-cells mature further in vivo after vaccination. theless, dendritic cell vaccine therapies have been Perambakam et al. [114] immunised patients with used against >20 different types of tumours. [105] autologous dendritic cells pulsed with PSA146-154 Thereby, peptides, recombinant proteins, tumour ly-peptide (binding to HLA-A2) [intravenous adminissates, messenger RNA (mRNA) and DNA have tration] or PSA146-154 peptide plus GM-CSF (inbeen used to deliver antigens to dendritic cells. tradermal injection). In this study, 28 HLA-A2 + Numerous clinical trials have demonstrated that patients with locally advanced or metastatic prostate vaccination of prostate cancer patients with dendrit-cancer were randomly assigned to one of these two ic cells is safe and can elicit a prostate cancer-methods. Strong delayed-type hypersensitivity skin specific immune response (table I) .
reactions to the PSA peptide became detectable in 50% (14 of 28) of patients over time. In this study,
Dendritic Cells Loaded with Peptides
half of the patients were vaccinated with immature monocyte-derived dendritic cells, which were culMurphy et al. [106] demonstrated the safe administured with GM-CSF and IL-4 for 7 days followed by tration of autologous dendritic cells in combination pulsing with PSA peptide and the influenza matrix with HLA-A0201-restricted peptides (named PSMprotein Flu-M1 peptide overnight. This procedure P1 and PSM-P2) derived from prostate-specific induced PSA-peptide-specific delayed-type hypermembrane antigen. Dendritic cells used in this study sensitivity responses in 5 of 14 patients, and specific were generated from adherent peripheral blood interferon-γ responses were observed in two of the mononuclear cells in the presence of GM-CSF and positive patients tested. The results of this study IL-4 for 4-6 days in vitro. Patients were vaccinated indicate that vaccination with soluble peptide or 4-5 times with autologous dendritic cells. Detection dendritic cell-bound peptide elicits strong specific of cellular response and decrease in PSA level in T-cell immunity to the PSA peptide in one-half of some patients who received dendritic cells pulsed patients with locally advanced or hormone-sensitive with PSM-P2 indicate the potential of this method in metastatic prostate cancer. prostate cancer therapy. A long-term observation of
In an attempt to induce a broader cytotoxic Tthese patients showed a response persisting for >200 cell response against prostate cancer cells, two indedays in some patients.
[109] Several follow-up studies pendent groups loaded autologous dendritic cells have demonstrated safety and a response in patients vaccinated with autologous dendritic cells loaded with different peptides derived from different pro-teins. [115, 116] Although tumour cells may evade im-data support the notion that only after repeated dendritic cell-based vaccinations over several months mune recognition by altering antigen processing, can an effect on progression of PSA values be multiple-epitope vaccination may overcome this poexpected. The investigators reported that even a tential limitation by maintaining immunological sufficiently stimulated immune system will not 'win pressure against different tumour-associated antithe uphill struggle' against an established rapidly gens. During immunotherapy, antigen loss may growing tumour and therefore proposed that treating even be promoted, as has previously been shown patients with earlier stage disease may not only with the emergence of melanoma antigen recogresult in successful therapy but also in clear clinical nised by T cells (MART)-1 negative melanoma mebenefits for patient. Both studies with dendritic celltastasis following adoptive transfer of MART-1-based multi-epitope immunotherapy used dendritic specific T cells. [128] Fuessel et al. [115] immunised cells generated from monocytes isolated from pe-HLA-A*0201 + patients with dendritic cells loaded ripheral blood mononuclear cells of prostate cancer. with a cocktail consisting of five different peptides Immature dendritic cells were matured in the presderived from PSA, prostate-specific membrane antience of IL-1β, TNFα, IL-6 and prostaglandin E2 gen, survivin, prostein and transient receptor poten-(PGE2). It has been reported that maturation-intial p8 (trp-p8).
[115] Four vaccinations every 2 weeks duced upregulation of chemokine receptor 7 were administered to eight patients. No adverse (CCR7) surface expression is not sufficient for moneffects other than local skin reactions were noted.
ocyte-derived dendritic cells to migrate toward their One patient displayed a partial response and three ligands CCL19 and CCL21. [129] [130] [131] Monocyte-deother patients showed stable PSA values or decelerrived dendritic cell migration toward CCL19 and ated PSA increases. ELISPOT analyses demonstrat-CCL21 was readily observed upon maturation in the ed that three of four PSA responders also showed presence of the proinflammatory mediator PGE2, antigen-specific CD8 + T-cell activation against although PGE2 did not change the expression level prostein, survivin and prostate-specific membrane of CCR7 on mature dendritic cells. Thus, PGE2 is an antigen. Waeckerle-Men et al.
[116] vaccinated six important element in the preparation of monocyte-HLA-A*0201 + patients with advanced hormone-derived dendritic cells as cellular vaccines in tumour refractory prostate cancer with autologous dendritic immunotherapy. cells pulsed with four different peptides derived from prostate stem cell antigen (PSCA14-22), pro-
Dendritic Cells Loaded with Proteins
static acid phosphatase (PAP299-307), prostate-specific membrane antigen (PSMA [4] [5] [6] [7] [8] [9] [10] [11] [12] and PSA Preclinical studies in rats demonstrated that den-(PSA154-163). Dendritic cells were intradermally ap-dritic cells loaded with prostatic acid phosphatase plied six times at 2-weekly intervals. Three patients linked to GM-CSF elicited strong cellular immune with enhanced immune responses were further vac-responses. Sipuleucel-T (APC8015) is an immucinated with monthly booster injections. Vaccina-notherapy product consisting of autologous antigention elicited significant cytotoxic T-cell responses presenting cells (CD54 + dendritic cells, but also against all PSAs tested and all long-term treated CD3 + , CD14 + , CD19 + and CD56 + cells) loaded ex patients demonstrated an increase in PSA doubling vivo with a recombinant fusion protein consisting of time, which correlated with the onset of interferon-γ prostatic acid phosphatase linked to GM-CSF. [117] production by cytotoxic T lymphocytes from the When Small et al.
[117] treated patients with hormoneperipheral blood after the sixth vaccination. These refractory prostate cancer with sipuleucel-T, den- Murphy et al., [106] [107] [108] Peptide-loaded DCs HLA-A0201-restricted peptides DCs generated from adherent PBMCs
Immunisation of prostate cancer Tjoa et al., [109] [110] [111] derived from PSA (named in the presence of GM-CSF and IL-4 for patients with DCs was safe
Salgaller et al., [112] PSM-P1 or PSM-P2)
4-6 days in vitro
Detection of cellular response and
Simmons et al. [113] decrease in PSA level observed in some patients GM-CSF applied as adjuvant did not significantly enhance immune response
Perambakam et al. [114] Peptide-loaded DCs HLA-A2 restricted peptides Barrou et al. [121] Protein-loaded DCs PSA DCs differentiated from monocytes with Maximum PSA decreased from 6% to GM-CSF and IL-13 for 7 days 39% PSA-specific T cells were detected in some patients
Fong et al. [122] Protein-loaded DCs dritic cell precursors matured during culture, as evi-ic cell function in tumour-bearing hosts. To investigate the effect of sipuleucel-T in combination with denced by upregulation of costimulatory molecules.
bevacizumab, a recombinant antibody against Sipuleucel-T seems to be safe and well tolerated.
VEGF, 22 patients with prostate cancer were treated There was no evidence of development of an with this combination therapy.
[120] All patients autoimmune disease caused by cross-reactivity bedemonstrated induction of an immune response tween the prostatic acid phosphatase antigen and the against prostatic acid phosphatase-GM-CSF fusion normal tissue component. All patients developed protein. One patient achieved a >50% reduction in immune responses to the recombinant fusion protein PSA and nine patients exhibited some decrease in used to prepare sipuleucel-T, and 38% developed PSA from baseline, ranging from 5% to 72%, with immune responses to prostatic acid phosphatase. In the PSA of three patients decreasing by ≥25%. The 10 of 26 patients, T cells specific for prostatic acid PSA-modulating and immune effects observed in phosphatase were discovered. Burch et al.
[119] treatthis combination study warrant further investigaed 13 patients with progressive hormone-refractory tion. metastatic prostate cancer with two infusions of sipuleucel-T administered 1 month apart followed Fong et al. [122] immunised 21 patients with metaby three subcutaneous monthly doses of prostatic static prostate cancer with 2-monthly injections of acid phosphatase-GM-CSF fusion protein alone. dendritic cells enriched from peripheral blood PSA levels were reduced by more than one-half in mononuclear cells. Following enrichment, the denthe course of treatment in three patients. T cells dritic cells developed an activated phenotype with drawn from patients after infusions of sipuleucel-T, upregulation of CD80, CD86 and CD83 expression, but not before, could be stimulated in vitro by GM-but CD62 ligand and CCR5 were lost during culture. CSF and prostatic acid phosphatase, demonstrating The investigators loaded dendritic cells in vitro with broken immune tolerance against these two proteins. prostatic acid phosphatase and administered the Recently, a placebo-controlled phase III trial with cells via different routes (intravenously, intradersipuleucel-T was conducted in patients with meta-mally and intralymphatically) to patients. All pastatic asymptomatic hormone-refractory prostate tients developed antigen-specific T-cell immune recancer.
[118] A total of 127 patients were randomly sponses following immunisation, regardless of the assigned in a 2 : 1 ratio to receive three infusions of route of injection but the quality of this response and sipuleucel-T or placebo every 2 weeks. Sipuleucel-T the induction of antigen-specific antibodies may was well tolerated, but this phase III trial did not have been affected by the route of administration. demonstrate an improvement in median time to disBarrou et al. [121] immunised prostatectomised ease progression. The median survival was 25.9 prostate cancer patients with autologous dendritic months for sipuleucel-T-treated patients and 21.4 cells pulsed with recombinant human PSA. Dendritmonths for placebo-treated patients. This 4.5-month ic cells were differentiated from monocytes with improvement in overall survival was statistically GM-CSF and IL-13 and were CD11c + , CD40 + , significant (p = 0.01). After 3 years, survival was CD80 + , CD86 + and HLA-DR + , but CD83 -. Patients 34% for those treated with the vaccine compared received nine administrations of PSA-loaded denwith 11% for those taking the placebo. dritic cells by combined intravenous, subcutaneous In animal models, inadequate dendritic cell dif-and intradermal routes over 21 weeks. PSA-specific ferentiation caused by tumour-derived factors, in-T cells were detected ex vivo by ELISPOT for cluding VEGF, may contribute to defective dendrit-interferon-γ in seven patients before vaccination and in 11 patients post-vaccination. Maximum PSA de-cytotoxic T-lymphocyte responses in vitro. [134] A crease ranged from 6% to 39%. similar approach was chosen by Su et al., [124] who vaccinated 20 patients with metastatic prostate can-
Dendritic Cells Pulsed with Cell Lysates
cer with hTERT mRNA-transfected dendritic cells. In order to direct hTERT antigen processing into In order to induce a broader spectrum of T cells, the MHC class II pathway, a lysosomal targeting Pandha et al. [123] immunised prostate cancer patients signal of lysosome-associated membrane protein-1 with allogeneic tumour lysate-pulsed dendritic cells.
(LAMP)-hTERT fusion protein can be used to transDelayed-type hypersensitivity skin testing and biopfect dendritic cells. Dendritic cells transfected with sy revealed a cellular infiltrate to intradermal re-LAMP-hTERT mRNA exhibited enhanced CD4 + Tchallenge with tumour lysate in almost all patients.
cell responses while allowing for concomitant inIn addition, there was increased expression of Th1 duction of hTERT-specific CD8 + T cells. In this cytokine interferon-γ in a few patients. Vaccination study by Su et al., [124] ex vivo-matured and electroresulted in a reduction in the level of PSA in one of nine evaluable patients and an increased PSA doub-porated dendritic cells were clinically applied for the ling time in six patients.
first time in human subjects with metastatic prostate cancer. Despite these modifications, the numbers of
Dendritic Cells Transfected with vaccine-induced T cells detected in the peripheral
Messenger RNA blood after three vaccination cycles did not appear to be strikingly different from those observed in a Use of mRNA to deliver antigens to dendritic previous clinical trial, in which immature monocytecells has several advantages: (i) antigens encoded by derived dendritic cells were passively transfected mRNA can contain multiple peptide epitopes for with PSA mRNA. [132] In the study by Su et al., [124] different MHC haplotypes; (ii) compared with pro-20 patients were vaccinated with hTERT mRNA or teins, mRNA can easily be synthesised; and (iii) in its chimeric form. In 19 of these patients, expansion contrast to DNA, mRNA carries little risk of integraof hTERT-specific CD8 + T cells was measured in tion into the host genome.
the peripheral blood. Patients immunised with the A phase I trial with 13 metastatic prostate cancer chimeric LAMP-hTERT vaccine developed signifipatients was performed to evaluate the safety, feasibility and efficacy of immunisation with autologous cantly higher frequencies of hTERT-specific CD4 + dendritic cells transfected with mRNA encoding T cells as well as enhanced cytotoxic T lymphocyte-PSA.
[132] Induction of PSA-specific T-cell responses mediated killing of hTERT + target cells. was consistently detected in all patients and a signifTo obtain a broader antigenicity, Mu et al. [125] icant decrease in log-slope PSA was observed in transfected dendritic cells with mRNA from alsix of seven evaluable patients. Because human logeneic prostate cancer cell lines (DU145, LNCaP telomerase reverse transcriptase (hTERT) is overexand PC-3). Twenty patients received at least four pressed in >85% of human solid tumours (including intranodal or intradermal weekly injections. The prostate cancer) but silent in normal tissues, this vaccine was safe and a total of 12 patients developed represents an attractive target for cancer immua specific immune response to tumour mRNA-transnotherapy. [133] It has previously been shown that fected dendritic cells. Thirteen patients exhibited a immunisation of mice with hTERT mRNA-transfected dendritic cells stimulates tumour-specific decrease in log-slope PSA.
Conclusions
tified for prostate cancer. So far, the classical prostate-specific proteins such as prostate-specific The development of new treatment options for membrane antigen, PSA, prostatic acid phosphatase metastatic prostate cancer patients is far from having and prostate stem cell antigen have been used to achieved a breakthrough in tumour vaccination. identify cytotoxic T-lymphocyte epitopes by 'reSeveral strategies, such as cytokine treatment, an-verse immunology'. However, these epitopes are far tibody therapy, DNA vaccination, viral vectors and from optimal because they are self-antigens, they dendritic cell immunotherapy, have been explored possess homologies to other broadly expressed in the battle against prostate cancer; however, cur-genes and they exist partially as soluble proteins in rent therapeutic approaches for metastatic prostate the blood. Non-secreted proteins such as six transcancer remain limited to a palliative role. Only three membrane epithelial antigen of the prostate, prostate approaches have demonstrated a minor increase in androgen-regulated transcript 1 or trp-p8 might be overall survival (although this parameter has not better candidates for epitopes for immunotherapy. been investigated in all studies): taxane-and plati-Furthermore, prostate cancer-specific tumour antinum-compound-based chemotherapy [16, 17, 19, 27] and gens such as mutated or overexpressed proteins have vaccination of patients with sipuleucel-T. [118] All to be identified. treatments provided a modest survival benefit of a A combination of different approaches to treat few months, but chemotherapy was also associated prostate cancer such as radiation or chemotherapy with significant adverse effects. Furthermore, one combined with immunotherapy might generate a has to ponder whether the complex and cost-inten-synergistic effect. At present, however, there resive procedure required to generate sipuleucel-T mains an urgent need for the development of novel justifies the only modest survival benefit seen with therapeutic strategies and improvements in current this agent. treatment modalities for prostate cancer. New molecules could be targeted with chemotherapeutic agents. However, it is highly unlikely Acknowledgements that any immunotherapy could elicit an immune response capable of eliminating a growing metastat- 
